A British-Swedish multinational biopharmaceutical leader in endocrinology boosted US sales revenue by 30% for its type-2 diabetes injectable device. Challenges included penetrating HCP share-of-mind amid entrenched competitors, overcoming loyalty to trusted devices needing credibility for switches, and lacking insights on HCP engagement/content patterns for personalized targeting. Indegene's software unlocked deep analytics on engagement behaviors and consumption, enabling hyper-personalized campaigns that built trust, drove device adoption, and shattered competitive barriers for substantial revenue growth.

Join for free to read